| P&L Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 234 | 250 | 272 |
| Cost of Material Consumed | 79 | 79 | 84 |
| Change in Inventory | 4 | -0.4 | 8 |
| Gross Margins | 64.53 | 68.56 | 66.18 |
| Employee Benefit Expenses | 77 | 90 | 94 |
| Other Expenses | 64 | 69 | 73 |
| EBITDA | 10 | 12.4 | 13 |
| OPM | 4.27 | 4.96 | 4.78 |
| Other Income | 0.08 | 0.12 | 0.15 |
| Finance Cost | 5 | 5 | 6 |
| D&A | 2 | 3 | 2 |
| EBIT | 8 | 9.4 | 11 |
| EBIT Margins | 3.42 | 3.76 | 4.04 |
| PBT | 2.4 | 4.5 | 4 |
| PBT Margins | 1.03 | 1.8 | 1.47 |
| Tax | 0.7 | 0.7 | 2 |
| PAT | 1.7 | 3.8 | 2 |
| NPM | 0.73 | 1.52 | 0.74 |
| EPS | 2.55 | 5.7 | 3 |
| Financial Ratios | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Profit Margin | 4.27 | 4.96 | 4.78 |
| Net Profit Margin | 0.73 | 1.52 | 0.74 |
| Earning Per Share (Diluted) | 2.55 | 5.7 | 3 |
| Assets | 2023 | 2024 | 2025 |
|---|---|---|---|
| Fixed Assets | 15 | 14 | 13 |
| CWIP | 0.2 | 0 | 1.35 |
| Investments | 0 | 0 | 0 |
| Trade Receivables | 109 | 123 | 149 |
| Inventory | 36 | 39 | 32 |
| Other Assets | 17.8 | 20 | 24.65 |
| Total Assets | 178 | 196 | 220 |
| Liabilities | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share Capital | 6.67 | 6.67 | 6.67 |
| FV | 10 | 10 | 10 |
| Reserves | 46 | 49 | 51 |
| Borrowings | 44 | 48 | 53 |
| Trade Payables | 46 | 50 | 64 |
| Other Liabilities | 35.33 | 42.33 | 45.33 |
| Total Liabilities | 178 | 196 | 220 |
| Cash-Flow Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| PBT | 2.4 | 4.5 | 4 |
| OPBWC | 9.4 | 12.4 | 12.5 |
| Change in Receivables | -19.8 | -17.3 | -26 |
| Change in Inventories | 7.8 | -2.8 | 7 |
| Change in Payables | 1.5 | 11.3 | 16 |
| Other Changes | 0 | 0 | -0.5 |
| Working Capital Change | -10.5 | -8.8 | -3.5 |
| Cash Generated From Operations | -1.1 | 3.6 | 9 |
| Tax | -2 | -1.3 | -3 |
| Cash Flow From Operations | -3.1 | 2.3 | 6 |
| Purchase of PPE | -1.9 | -1.3 | -3.2 |
| Sale of PPE | 0.2 | 0.2 | 0.4 |
| Cash Flow From Investment | -1.7 | -1.1 | -2.8 |
| Borrowing | 9.3 | 3 | 6 |
| Dividend | -0.8 | -0.4 | -0.5 |
| Equity | 0 | 0 | 0 |
| Others From Financing | -4.6 | -5.5 | -5.96 |
| Cash Flow from Financing | 3.9 | -2.9 | -0.46 |
| Net Cash Generated | -0.9 | -1.7 | 2.74 |
| Cash at the Start | 8.2 | 7.3 | 5.59 |
| Cash at the End | 7.3 | 5.6 | 8.33 |
East India Pharmaceutical Works Limited is one of India’s longstanding pharmaceutical companies, known for its strong legacy in manufacturing high-quality medicines and healthcare products. Established with a commitment to affordable healthcare, the company has built a robust presence in both domestic and international markets over the decades. Its product portfolio spans a wide range of therapeutic categories including anti-infectives, gastrointestinal medicines, vitamins, analgesics, and specialty formulations. With well-equipped manufacturing units, strict quality-control standards, and a focus on research-driven processes, East India Pharmaceutical Works has maintained a reputation for reliability, consistency, and ethical pharmaceutical practices.
The company’s success is rooted in its integrated operational model, which combines modern production capabilities with deep experience in pharmaceutical science. Over the years, East India Pharmaceutical Works has expanded its distribution networks, ensuring that its products reach urban centers as well as underserved rural markets. Its emphasis on continuous improvement, regulatory compliance, and product diversification has enabled the company to remain competitive in the fast-evolving healthcare industry. By investing in new technologies, skilled professionals, and advanced testing facilities, the company ensures that every product adheres to rigorous safety and efficacy standards, strengthening its position as a trusted healthcare provider.
Looking ahead, East India Pharmaceutical Works Limited is focused on scaling its research initiatives, enhancing manufacturing efficiency, and expanding its therapeutic offerings to meet the growing healthcare needs of India and global markets. With rising demand for quality medicines and an increasing emphasis on preventive healthcare, the company is well-positioned to capture future growth opportunities. Its strategic vision includes exploring new export markets, strengthening partnerships, and adopting digital tools to improve operational performance. As the pharmaceutical sector continues to grow, East India Pharmaceutical Works remains committed to delivering accessible, high-quality medicines while contributing to the broader goal of improving public health.
Q:1 How do I confirm my booking for East India Pharmaceutical Works Limited Unlisted Shares?Answer: You can confirm your booking by contacting us and agreeing on a trading price for the shares you wish to purchase.
Q:2 What documents do I need to provide to buy shares?Answer: You need to provide your client master report, PAN Card, and a cancelled cheque unless you are transferring funds from the bank account mentioned in your client master report.
Q:3 Why are KYC documents required for purchasing shares?Answer: KYC documents are required to comply with SEBI regulations, ensuring that the transaction is legitimate and that the identity of the investor is verified.
Q:4 How will I receive the bank details for payment?
Answer: We will provide you with the necessary bank details once your booking is confirmed.
Q:5 What payment methods are accepted for purchasing shares?
Answer: Payments can be made using RTGS, NEFT, IMPS, or cheque transfer.Cash deposits are not accepted.
Q:6 Can I use a different bank account for payment than the one listed in my client master report?Answer: No, payment must be made from the same bank account where the shares are to be credited.
Q:7 Is there a specific time frame for making the payment?Answer: While the payment timeframe may vary, it is advisable to make the payment as soon as possible after confirming your booking to ensure a smooth transaction.
Q:8 What happens if I do not provide the required KYC documents?Answer: If you do not provide the required KYC documents, your transaction may not be processed, and you will be unable to purchase the shares.